A 12-month clinical investigation with a 24-day regimen containing 15 μg ethinylestradiol plus 60 μg gestodene with respect to hemostasis and cycle control

Contraception

Volumn 63, Issue 6, 2001, Pages 303-307

  Fruzzetti, Franca ^a   Genazzani, Andrea Riccardo ^a   Ricci, Cabiria ^a   Negri, Ferdinando De ^a   Bersi, Chiara ^a   Carmassi, Franco ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cycle control; Gestodene; Hemostasis; Oral contraceptives

Indexed keywords

ANTIGEN; ANTITHROMBIN III; ETHINYLESTRADIOL PLUS GESTODENE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG USE; EVALUATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; INCIDENCE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NORMAL HUMAN; PILL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CONTRACEPTIVES, ORAL, SYNTHETIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHINYL ESTRADIOL; FEMALE; HEMOSTASIS; HUMANS; MENSTRUAL CYCLE; NORPREGNENES; TIME FACTORS; WHOLE BLOOD COAGULATION TIME;

EID: 0034792208     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(01)00213-X     Document Type: Article

References (18)

1. Oral contraceptives, clotting factors and thrombosis
2. Fibrinopeptide A plasma levels during low-dose oral contraceptive treatment
3. Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives
4. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women
5. Effects of oral contraceptives on haemostasis variables
6. A comparative study of the effects on the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg, and 30 μg EE
7. Hormone replacement therapy and haemostasis: Principles of a complex interaction
8. A randomized controlled double-blind study of the effects on haemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel
9. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 mcg EE, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors
10. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives
11. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg
12. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus
13. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinylestradiol (Alesse)
14. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestoden, and 30 micrograms ethinylestradiol/75 micrograms gestoden, with respect to efficacy, cycle control, and tolerance
15. Three years' clinical experience with a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene: Efficacy, cycle control, and tolerability
16. A clinical overview of a new triphasic contraceptive containing gestodene
17. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 μg/ethinylestradiol 15 μg and 21-day regimen of desogestrel 150 μg/ethinylestradiol 20 μg
18. A comparative study of the effects of gestodene 60 μg/ethinylestradiol 15 μg, and desogestrel 150 μg/ethinylestradiol 20 μg on hemostatic balance, blood lipid levels, and carbohydrate metabolism